28PD - Measuring the population impact of introducing stereotactic ablative radiotherapy (SABR) for stage I NSCLC in Canada
|Date||28 March 2014|
|Session||Poster Discussion 2|
|Topics|| Non-Small-Cell Lung Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A.V. Louie1, G.B. Rodrigues2, D.A. Palma2, S. Senan3
SABR achieves long-term local control rates of up to 90% in stage I NSCLC. We used the Cancer Risk Management Model (CRMM) to estimate the health and economic impact of introducing SABR for stage I NSCLC in Canada.